Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1 Study of Rebecsinib, a Spliceosome Modulator That Inhibits ADAR1, in Patients With Relapsed or Refractory Secondary Acute Myeloid Leukemia or Higher-Risk Myelofibrosis

The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either …

Secondary AMLMyelofibrosis

Aspera Biomedicines, Inc.NCT07250646